Abstracts tagged "spondyloarthritis"

Abstract Number: 0398 • ACR Convergence 2022
Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
Benjamin Naovarat¹, John Reveille¹, Mark Hwang², Francis Williams³ and Gloria Salazar⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³Specialists for Health/Wellmed, Shavano Park, TX, ⁴University of Texas Medical School at Houston/McGovern Medical School, Houston, TX
Background/Purpose: Early in the HIV epidemic, autoimmune diseases such as lupus and rheumatoid arthritis (RA) were uncommonly encountered. With the advent of combined antiretroviral therapy…
Abstract Number: 0427 • ACR Convergence 2022
Recapture Rates with Ixekizumab After Withdrawal of Therapy in Patients with Axial Spondyloarthritis: Results at Week 104 from a Randomized Placebo-controlled Withdrawal Study
Robert Landewé¹, Denis Poddubnyy², Proton Rahman³, Rebecca Bolce⁴, Soyi Liu-Leage⁵, Jeffrey Lisse⁶, So Young Park⁷ and Lianne Gensler⁸, ¹Amsterdam University Medical Center, Meerssen, Netherlands, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Memorial University, St. John's, NL, Canada, ⁴Eli Lilly and Company, Cincinnati, OH, ⁵Eli Lilly, Neuilly sur Seine, France, ⁶Eli Lilly and Company, Tucson, AZ, ⁷Eli Lilly and Company, Indianapolis, IN, ⁸Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Here, we describe the final results of the first study of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis re-randomized to either placebo (ixekizumab…
Abstract Number: 1010 • ACR Convergence 2022
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints of Axial Spondyloarthritis Patients and Implications for Recruitment in Clinical Studies
Xenofon Baraliakos¹, Pedro Machado², Lars Bauer³, Bengt Hoepken³, Mindy Kim⁴, Thomas Kumke³, Rachel Tham⁵ and Martin Rudwaleit⁶, ¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²University College London, London, United Kingdom, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) recently proposed preliminary, more stringent, data-driven definitions for active and structural MRI lesions of the sacroiliac joint…
Abstract Number: 1156 • ACR Convergence 2022
Serum Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Is Increased in Patients with Active Ankylosing Spondylitis (AS) and Persists Despite Anti-TNF Treatment
Charalampos Papagoras¹, Styliani Tsiami², Akrivi Chrysanthopoulou¹, Ioannis Mitroulis¹ and Xenofon Baraliakos³, ¹First Department of Internal Medicine and Laboratory of Molecular Hematology, University Hospital of Alexandroupolis, Democritus University of Thrace, Alexandroupolis, Greece, ²Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet Herne, Herne, Germany
Background/Purpose: There is increasing evidence of the pathogenetic role of monocytes and neutrophils in AS, while the neutrophil-to-lymphocyte ratio correlates with disease activity (1). Granulocyte-Monocyte…
Abstract Number: 1492 • ACR Convergence 2022
Treatment with Non-steroidal Anti-inflammatory Drugs Is Associated with Retardation of Radiographic Spinal Progression in Patients with Axial Spondyloarthritis: 10-year Results from the GErman SPondyloarthritis Inception Cohort
Murat Torgutalp¹, valeria Rios-Rodriguez², Ani Dilbaryan³, Fabian Proft⁴, Mikhail Protopopov⁵, Maryna Verba⁶, Judith Rademacher⁵, Hildrun Haibel¹, Joachim Sieper¹, Martin Rudwaleit⁷ and Denis Poddubnyy⁴, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Charité-Universitätsmedizin Berlin, Berlin, Germany, ³Department of Internal Medicine, Moscow City Clinical Hospital, Moscow, Russia, ⁴Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité-Universitätsmedizin Berlin, corporate member of Freie-Universitat Berlin and Humboldt-Universitat zu Berlin, Department of Gastroenterology, Infectious Diseases and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium
Background/Purpose: There are conflicting data regarding the effect of nonsteroidal anti-inflammatory drugs (NSAID) on radiographic spinal progression in axial spondyloarthritis (axSpA). The analysis of the…
Abstract Number: 1771 • ACR Convergence 2022
The Effectiveness of a Treat-to-target Strategy in Rheumatic Diseases: A Systematic Literature Review and Meta-analysis
Yanjie Hao¹, Shereen Oon² and Mandana Nikpour³, ¹The University of Melbourne, Melbourne, Australia, ²The University of Melbourne Department of Medicine at St. Vincent’s Hospital Melbourne, Melbourne, Australia, ³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia
Background/Purpose: The concept of treat-to-target (T2T), a strategy in which treatment is directed to reach and maintain a defined goal such as remission or low…
Abstract Number: PP25 • ACR Convergence 2022
From Denial of Spondyloarthritis to Becoming a Support Group Leader and Medical Doctor of Rheumatology: A Patient’s Perspective
Shung Chiu¹ and Mei Nee Chiu², ¹Spondylitis Association of America, Ludhiana, Punjab, India, ²University Institute of Pharmaceutical Sciences, Panjab University, Ludhiana, Punjab, India
Background/Purpose: From being a table tennis champion to getting into medical school, I thought my life was smooth sailing. But little did I know it…
Abstract Number: 0399 • ACR Convergence 2022
ASAS Recommendations for Requesting and Reporting Imaging in Patients with Suspected Axial Spondyloarthritis
Torsten Diekhoff¹, Iris Eshed², Chiara Giraudo³, Hildrun Haibel⁴, Kay-Geert Hermann⁵, Manouk de Hooge⁶, Lennart Jans⁷, Anne Jurik⁸, Robert G Lambert⁹, Pedro Machado¹⁰, Walter P Maksymowych¹¹, Michael Mallinson¹², Helena Marzo-Ortega¹³, Victoria Navarro-Compán¹⁴, Susanne Pedersen¹⁵, Mikkel Østergaard¹⁶, Monique Reijnierse¹⁷, Martin Rudwaleit¹⁸, Fernando Andres Sommerfleck¹⁹, Ulrich Weber²⁰, Xenofon Baraliakos²¹ and Denis Poddubnyy²², ¹Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Sheba Medical Center, Tel Aviv, Israel, ³University of Padova, Padova, Italy, ⁴Charité - Universitätsmedizin, Berlin, Berlin, Germany, ⁵Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁶Ghent University Hospital, Luxembourg, Luxembourg, ⁷Ghent University Hospital, Ghent, Belgium, ⁸Aarhus University Hospital, Aarhus, Denmark, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰University College London, London, United Kingdom, ¹¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ¹²ASIF Axial Spondyloarthritis International Federation, London, United Kingdom, ¹³Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ¹⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ¹⁵Rigshospitalet, København, Denmark, ¹⁶Rigshospitalet, University of Copenhagen, Glostrup, Denmark, ¹⁷Leiden University Medical Center, Leiden, Netherlands, ¹⁸University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ¹⁹Sanatorio Julio Mendez, Buenos Aires, Argentina, ²⁰Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ²¹Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ²²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Clinicians face uncertainties in their daily practice when requesting imaging for patients with suspicion of axial spondyloarthritis (axSpA) or producing a report because requirements…
Abstract Number: 0542 • ACR Convergence 2022
ASAS-EULAR Recommendations for the Management of Axial Spondyloarthritis: 2022 Update
Sofia Ramiro¹, Elena Nikiphorou², Alexandre Sepriano³, Augusta Ortolan⁴, Casper Webers⁵, Xenofon Baraliakos⁶, Robert Landewé⁷, Filip Van den bosch⁸, Boryana Boteva⁹, Ann Bremander¹⁰, Philippe Carron¹¹, Adrian Ciurea¹², floris van Gaalen¹, Pal Geher¹³, Lianne Gensler¹⁴, Josef Hermann¹⁵, Manouk de Hooge¹⁶, Marketa Husakova¹⁷, Uta Kiltz¹⁸, Clementina Lopez-Medina¹⁹, Pedro Machado²⁰, Helena Marzo-Ortega²¹, Anna Molto²², Victoria Navarro-Compán²³, Michael Nissen²⁴, Fernando Pimentel-Santos²⁵, Denis Poddubnyy²⁶, Fabian Proft²⁶, Martin Rudwaleit²⁷, Mark Telkman⁹, Sizheng Zhao²⁸, Nelly Ziade²⁹ and Désirée van der Heijde³⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center & King's College London, London, United Kingdom, ³Leiden University Medical Centre, Portela Loures, Portugal, ⁴University of Padova/Leiden University Medical Center, Padova, Italy, ⁵Maastricht University Medical Centre, Maastricht, Netherlands, ⁶Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁷Amsterdam University Medical Center, Meerssen, Netherlands, ⁸Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ⁹Patients with Arthritis and Rheumatism (PARE) working group, EULAR, Zürich, Switzerland, ¹⁰Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark, ¹¹Ghent University Hospital, Ghent, Belgium, ¹²University Hospital Zurich, Zürich, Switzerland, ¹³Semmelweis University, Budapest, Hungary, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ¹⁵Medical University of Graz, Graz, Austria, ¹⁶Ghent University Hospital, Luxembourg, Luxembourg, ¹⁷Department of Rheumatology, First Faculty of Medicine, Charles University and Rheumatology Institute, Prague, Prague, Czech Republic, ¹⁸Rheumazentrum Ruhrgebiet, Herne, Germany, ¹⁹Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ²⁰University College London, London, United Kingdom, ²¹Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ²²Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France, ²³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ²⁴Hopitaux Universitaires de Genève, Geneva, Switzerland, ²⁵NOVA Medical School; Universidade NOVA e Lisboa, Lisboa, Portugal, ²⁶Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ²⁸University of Manchester, Liverpool, United Kingdom, ²⁹Saint-Joseph University, Beirut, Lebanon, ³⁰Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands
Background/Purpose: Since the last update of the ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) in 2016, substantial new evidence has become available on…
Abstract Number: 1013 • ACR Convergence 2022
Discriminatory Capacity of the ASAS Health Index in Patients with Axial Spondyloarthritis Treated in a Tight Control Setting versus Standard of Care
Uta Kiltz¹, Anna Molto², Clementina Lopez-Medina³, Maxime Dougados⁴, Désirée van der Heijde⁵, Annelies Boonen⁶, Filip Van den bosch⁷ and Juergen Braun¹, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumatology Department, Cochin Hospital, APHP, Paris, France, ³Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, ⁴Department of Rheumatology, Hôpital Cochin, Paris, France, Paris, France, ⁵Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ⁶Maastricht University Medical Centre, Maastricht, Netherlands, ⁷Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium
Background/Purpose: Improvement in functioning and health as assessed by the ASAS Health Index (HI) is an important outcome of interventions in patients with axial spondyloarthritis…
Abstract Number: 1157 • ACR Convergence 2022
Bacterial Indole Associated with Spondyloarthritis-Related Dysbiosis Contributes to Enhanced Th17 Immunity
Brenda Seymour¹, Brandon Trent², Brendan Allen³, Adam Berlinberg¹ and Kristi Kuhn³, ¹University of Colorado Anschutz Medical Campus, Denver, CO, ²University of Colorado Anschutz Medical Campus, Eugene, OR, ³University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: While intestinal dysbiosis and the Th17 pathway are linked to the pathophysiology of spondyloarthritis (SpA), the mechanisms by which this occurs are unknown. We…
Abstract Number: 1494 • ACR Convergence 2022
Determinants of Clinically Important Worsening in Early Axial Spondyloarthritis: Analysis of the DESIR Cohort over 5 Years
Faten Hamitouche¹, Sushmitha Kumaradev¹, Désirée van der Heijde², Sofia Ramiro³, Alexandre Sepriano⁴ and Anna Molto⁵, ¹INSERM U-1153, Université Paris-Cité, CRESS, Paris, France, ²Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ³Leiden University Medical Center, Leiden, Netherlands, ⁴Leiden University Medical Centre, Portela Loures, Portugal, ⁵Rheumatology Department, Hôpital Cochin,Assistance Publique- Hôpitaux de Paris, Paris, France
Background/Purpose: A definition for clinically important worsening (CIW) of axial Spondyloarthritis (axSpA) has been proposed by ASAS: i.e. an increase of ≥0.9 points of ASDAS.…
Abstract Number: 2117 • ACR Convergence 2022
Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomized, Placebo-Controlled Studies
Philip J Mease¹, Laura Coates², Robert Landewé³, Iain B McInnes⁴, Christopher Ritchlin⁵, Tatsuya Atsumi⁶, Frank Behrens⁷, Dafna Gladman⁸, Laure Gossec⁹, Peter Nash¹⁰, Barbara Ink¹¹, Deepak Assudani¹¹, Rajan Bajracharya¹¹, Jason Coarse¹², Adam R Prickett¹³ and Alice Gottlieb¹⁴, ¹Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom, ³Amsterdam University Medical Center, Meerssen, Netherlands, ⁴Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Hokkaido University, Sapporo, Japan, ⁷Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁸Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ⁹Sorbonne Université, Paris, France, ¹⁰School of Medicine, Griffith University, Sunshine Coast, Australia, ¹¹UCB Pharma, Slough, United Kingdom, ¹²UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹³UCB Pharma, Brussels, Belgium, ¹⁴Department of Dermatology, The Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across…
Abstract Number: 0406 • ACR Convergence 2022
Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Quality of Life in Women with Axial Spondyloarthritis?
Sinead Maguire¹, Fiona Wilson², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James' Hospital, Dublin, Ireland, ²Trinity College Dublin, Dublin, Ireland, ³St Vincent's University Hospital, Dublin, Ireland
Background/Purpose: The tools to assess disease activity and quality of life in axial spondyloarthritis (axSpA) were developed in ankylosing spondylitis cohorts biased towards inclusion of…
Abstract Number: 0543 • ACR Convergence 2022
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Martin Rudwaleit¹, Filip Van den bosch², Helena Marzo-Ortega³, Victoria Navarro-Compán⁴, Rachel Tham⁵, Thomas Kumke⁶, Lars Bauer⁶, Mindy Kim⁷ and Lianne Gensler⁸, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld; Germany Klinikum Bielefeld and Charité Berlin, Germany, and Gent University, Gent, Belgium, ²Department of Internal Medicine and Paediatrics, Ghent University and VIB Centre for Inflammation Research, Ghent, Belgium, ³Leeds Teaching Hospitals Trust and University of Leeds, Leeds, United Kingdom, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵UCB Pharma, Slough, UK, Overland Park, KS, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Smyrna, GA, ⁸Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: In clinical trials of axial spondyloarthritis (axSpA), composite measures such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) response criteria, Assessment of Spondyloarthritis international…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].